Abstract
Background Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13. It is approved in the U.S.A. for patients aged >= 12 ye......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
